Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial

Back

ESC2025 Premium Access

Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial

Session: What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Topic: Cardiovascular Pharmacotherapy

Speaker: Doctor J. Plutzky (Boston, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

5 presentations

0 follower

5 more presentations in this session

Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial

Speaker: Professor R. Pop-Busui (Portland, US)

Vagal activity related events and GLP-1 receptor agonists

Speaker: Mr A. Holt (Copenhagen, DK)

Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population

Speaker: Doctor P. Yazdanfard (Hilleroed, DK)

Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population

Speaker: Ms K. Soerensen (Copenhagen, DK)

Effects of SGLT2 inhibitors on triglyceride-derived indices among coronary heart disease patients with varying diabetes control status: a prospective cohort study

Speaker: Professor N. Wu (Beijing, CN)

Access the full session

What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Speakers: Doctor J. Plutzky, Professor R. Pop-Busui, Mr A. Holt, Doctor P. Yazdanfard, Ms K. Soerensen...

Access

Video

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources